Vaccine adjuvants: Current state and future trends
Nikolai Petrovsky
Autoimmunity Research Unit, ANU Medical School, Australian National University, Canberra, ACT 2061 Australia
Search for more papers by this authorJulio César Aguilar
Vaccines Division, Center for Genetic Engineering and Biotechnology, Ave. 31 e/158 y 190, Cubanacán, Apdo, 6162 Ciudad, Habana, Cuba
Search for more papers by this authorNikolai Petrovsky
Autoimmunity Research Unit, ANU Medical School, Australian National University, Canberra, ACT 2061 Australia
Search for more papers by this authorJulio César Aguilar
Vaccines Division, Center for Genetic Engineering and Biotechnology, Ave. 31 e/158 y 190, Cubanacán, Apdo, 6162 Ciudad, Habana, Cuba
Search for more papers by this authorAbstract
The problem with pure recombinant or synthetic antigens used in modern day vaccines is that they are generally far less immunogenic than older style live or killed whole organism vaccines. This has created a major need for improved and more powerful adjuvants for use in these vaccines. With few exceptions, alum remains the sole adjuvant approved for human use in the majority of countries worldwide. Although alum is able to induce a good antibody (Th2) response, it has little capacity to stimulate cellular (Th1) immune responses which are so important for protection against many pathogens. In addition, alum has the potential to cause severe local and systemic side-effects including sterile abscesses, eosinophilia and myofascitis, although fortunately most of the more serious side-effects are relatively rare. There is also community concern regarding the possible role of aluminium in neurodegenerative diseases such as Alzheimer's disease. Consequently, there is a major unmet need for safer and more effective adjuvants suitable for human use. In particular, there is demand for safe and non-toxic adjuvants able to stimulate cellular (Th1) immunity. Other needs in light of new vaccine technologies are adjuvants suitable for use with mucosally-delivered vaccines, DNA vaccines, cancer and autoimmunity vaccines. Each of these areas are highly specialized with their own unique needs in respect of suitable adjuvant technology. This paper reviews the state of the art in the adjuvant field, explores future directions of adjuvant development and finally examines some of the impediments and barriers to development and registration of new human adjuvants.
References
- 1Bomford R. Will adjuvants be needed for vaccines of the future. In: F Brown, LR Haaheim, (eds). Modulation of the Immune Response to Vaccine Antigens. Dev. Biol. Stand, Vol. 92. Basel: Karger 1998; 13–8.
- 2Vogel FR. Adjuvants in Perspective. In: F Brown, LR Haaheim, (eds). Modulation of the Immune Response to Vaccine Antigens. Dev. Biol. Stand, Vol. 92. Basel: Karger 1998; 241–8.
- 3Ramon G. Sur l'augmentation anormale de l'antitoxine chez les chevaux producteurs de serum antidiphterique. Bull. Soc. Centr. Med. Vet 1925; 101: 227–34.
- 4Ramon G. Procedes pour accroïtre la production des antitoxins. Ann. Inst. Pasteur 1926; 40: 1–10.
- 5Glenny AT, Pope CG, Waddington H, Wallace V. The antigenic value of toxoid precipitated by potassium-alum. J. Path. Bacteriol. 1926; 29: 38–45.
10.1002/path.1700290106 Google Scholar
- 6Vogel FR, Powell MF. A summary compendium of vaccine adjuvants and excipients. In: MF Powell, MJ Newman (eds). Vaccine Design: the Subunit and Adjuvant Approach, New York: Plenum Publishing Corp, 1995; 234–50.
10.1007/978-1-4615-1823-5_7 Google Scholar
- 7Freund J, Casals J, Hosmer EP. Sensitization and antibody formation after injection of tubercle bacili and parafin oil. Proc. Soc. Exp. Biol. Medical 1937; 37: 509–13.
- 8Stuart-Harris CH. Adjuvant influenza vaccines. Bull. WHO 1969; 41: 617–21.
- 9Johnson AG, Gaines S, Landy M. Studies on the O-antigen of Salmonella typhosa V. Enhancement of antibody response to protein antigens by the purified lipopolysaccharide. J. Exp. Med. 1956; 103: 225–46.
- 10Ribi E. Beneficial modification of the endotoxin molecule. J. Biol. Response Mod. 1984; 3: 1–9.
- 11Ellouz F, Adam A, Ciobaru R, Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptido glycan derivates. Biochem. Biophys. Res. Commun. 1974; 59: 1317–25.
- 12Weiner GJ, Hsin-Ming L, Wooldridge JE, Dahle CE, Krieg AM. Immunostimulatory oligodeoxynucletides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl Acad. Sci. USA 1997; 94: 10833–7.
- 13McElrath MJ. Selection of potent immunological adjuvants for vaccine construction. Seminars Cancer Biol. 1995; 6: 375–85.
- 14Marx PA, Compans RW, Gettie A. Protection against vaginal SIV transmition with microencap-sulated vaccine. Science 1993; 28: 1323–7.
- 15Douce G, Turcotte C, Cropley I et al. Mutants of Escherichia coli heat-labile toxin lacking ADP ribosyl-transferase activity act as non-toxic mucosal adjuvants. Proc. Natl Acad. Sci. USA 1995; 92: 1644–8.
- 16Lindblad EB. Aluminium Adjuvants. In: DES Stewart-Tull (ed.) The Theory and Practical Application of Adjuvants. Chichester: John Wiley & Sons Ltd, 1995; 21–35.
- 17Byars NE, Allison AC. Immunologic adjuvants: general properties, advantages, and limitations. In: H Zola (ed.) Laboratory Methods in Immunology. Boca Raton: CRC Press, 1990; 39–51.
- 18Edelman R. Vaccine Adjuvants. Rev. Infect. Dis. 1980; 2: 370–83.
- 19Neutra MR, Pringault E, Kraehenbuhl JP. Antigen sampling across epithelial barriers and induction of mucosal immune responses. Annu. Rev. Immunol. 1996; 14: 275–300.
- 20Warren HS, Chedid LA. Future prospects for vaccine adjuvants. CRC Crit. Rev. Immunol. 1986; 4: 369–88.
- 21Edelman R. An update on vaccine adjuvants in clinical trials. AIDS Res. Hum. Retroviruses 1992; 8: 1409–11.
- 22Allison AC, Byars NE. Immunological adjuvants: desirable properties and side-effects. Mol. Immunol. 1991; 28: 279–84.
- 23Waters RV, Terrell TG, Jones GH. Uveitis induction in the rabbit by muramyl dipeptides. Infect. Immunol. 1986; 51: 816–25.
- 24Goldenthal KL, Cavagnaro JA, Alving CR, Vogel FR. Safety evaluation of vaccine adjuvants. National Cooperative Vaccine Development Working Group. AIDS Res. Hum. Retroviruses 1993; 9: S45–S49.
- 25Stewart-Tull DES. Recommendations for the assessment of adjuvants. In: G Gregoriadis, AC Allison, G Poste (eds). Immunological Adjuvants and Vaccines. New York: Plenun Press, 1989; 213–26.
10.1007/978-1-4757-0283-5_22 Google Scholar
- 26Edelman R, Tacket C. Adjuvants. International Rev. Immunol 1990, 1992; 7: 51–66.
10.3109/08830189009061764 Google Scholar
- 27Jennings R, Simms JR, Heath AW. Adjuvants and Delivery Systems for Viral Vaccines-Mechanisms and Potential. In: F Brown, LR Haaheim, (eds). Modulation of the Immune Response to Vaccine Antigens. Dev. Biol. Stand, Vol. 92. Basel: Karger 1998; 19–28.
- 28Schirmbeck R, Melber K, Mertens T, Reimann J. Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implications for the pathogenesis of HBV-induced hepatitis. J. Virol. 1994; 68: 1418–25.
- 29Traquina P, Morandi M, Contorni M, van Nest G. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J. Infect. Dis. 1996; 174: 1168–75.
- 30Brewer JM, Conacher M, Satoskar A, Bluethmann H, Alexander J. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Eur J. Immunol. 1996; 26: 2062–6.
- 31Blagowechensky NN. Durée du séjour de l'antigène dans l'organisme et immunité. Rev. Immunol. París 1938; 4: 161.
- 32Walls RS. Eosinophil response to alum adjuvants. Involvement of T cells in non-antigen-dependent mechanisms. Proc. Soc. Exp. Biol. Medical 1977; 156: 431–5.
- 33Gupta RK, Rost BE, Relyveld E, Siber GR. Adjuvant Properties of Aluminium and Calcium Compounds. In: MF Powell, MJ Newman (eds). Vaccine Design: the Subunit and Adjuvant Approach, New York: Plenum Press 1995; 229–48.
- 34Butler NR, Voyce MA, Burland WL, Hilton ML. Advantages of aluminum hydroxide adsorbed diphtheria, tetanus and pertussis vaccines for the immunization of infants. Br. Med. J. 1969; 1: 663–6.
- 35Straw BE, MacLachlan NJ, Corbett WT, Carter PB, Schey HM. Comparison of tissue reactions produced by Haemophilus pleuropneumoniae vaccines made with six different adjuvants in swine. Can. J. Comp. Med. 1985; 49: 149.
- 36Audibert FM, Lise LD. Adjuvants: current status, clinical perspectives and future prospects. Immunol. Today 1993; 14: 281–4.
- 37Bomford R. Aluminium salts: perspectives in their use as adjuvants. In: G Gregoriadis, AC Allison, G Poste (eds). Immunological Adjuvants and Vaccines. New York: Plenum Press 1989; 35–41.
- 38Goto N, Kato H, Maeyama J-I, Eto K, Yoshihara S. Studies on the toxicities of aluminium hydroxide and calcium phosphate as immunological adjuvants for vaccines. Vaccine 1993; 11: 914–8.
- 39Relyveld EH, Hencoq E, Raynaud M. Etude de la vaccination antidiphterique de sujets alergiques avec une anatoxine pure adsorbee sur phosphate de calcium. Bull. WHO 1964; 30: 321–5.
- 40Gupta RK, Siber GR. Adjuvants for human vaccines-current status, problems and future prospects. Vaccine 1995; 13: 1263–76.
- 41Relyveld EH. Preparation and use of calcium phosphate adsorbed vaccines. Dev. Biol. Stand. 1986; 65: 131–6.
- 42Kensil CR. Saponins as vaccine adjuvants. Crit. Rev. Ther. Drug Carrier Syst. 1996; 13: 1–55.
- 43Takahashi H, Takeshita T, Morein B, Putney S, Germain RN, Berzofsky JA. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 1990; 344: 873–5.
- 44Dalsgaard K. Adjuvants. Vet Immunol. Immunopathol. 1987; 17: 145–53.
- 45Bomford RHR. The differential adjuvant activity of Al (OH) 3 and saponin. In: J Madje (ed.) Immunopharmacology of Infectious Diseases: Vaccine Adjuvants and Modulators of Non-Specific Resistance, New York: Alan R. Liss 1987; 65–70.
- 46Rönnberg B, Fekadu M, Morein B. Adjuvant activity of non toxic Quillaja saponaria Molina components for use in iscom-matrix. Vaccine 1995; 13: 1375–82.
- 47Kensil CR, Patel U, Lennick M, Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol. 1991; 146: 431–7.
- 48Kensil CR, Wu J-Y, Soltysik S. Structural and immunological characterization of the vaccine adjuvant QS-21. In: MF Powell, MJ Newman (eds). Vaccine DesignThe Subunit and Adjuvant Approach 1995; New York: Plenum Press 525–41.
10.1007/978-1-4615-1823-5_22 Google Scholar
- 49Kotani S, Watanabe Y, Shimoto T et al. Immunoadjuvant activities of cells walls, their water soluble fractions and peptidoglycan subunits, prepared from various gram-positive bacteria, and of synthetic N-acetylmuramyl peptides. Z. Immunitatsforsch. 1975; 149S: 302–5.
- 50Audibert F, Leclerc C, Chedid L. Muramyl peptides as immunopharmacological response modifiers In: PF Torrence (ed.) Biological Response ModifiersNew Approaches to Disease Prevention. Orlando: Academic Press, 1985; 307.
10.1016/B978-0-12-695770-9.50018-0 Google Scholar
- 51Audibert F, Chedid L, Lefrancier P, Choay J. Distinctive adjuvanticity of synthetic analogs of mycobacterial water-soluble components. Cell Immunol. 1976; 21: 243–5.
- 52Parant MA, Audibert FM, Chedid LA et al. Immunostimulant activities of a lipophilic muramyl dipeptide derivative and of a desmuramyl peptidolipid analogue. Infect. Immun. 1980; 27: 826–30.
- 53Leclerc C, Vogel F. Synthetic immunomodulators and synthetic vaccines. CRC Crit. Rev. Ther. Drug Carrier Syst. 1986; 2: 353–7.
- 54Tomai MA, Johnson AG. T cell and interferon-g involvement in the adjuvant action of a detoxified endotoxin. J. Biol. Resp. Modifiers 1989; 8: 625–30.
- 55Lemaire G, Tenu JP, Petit JF, Lederer E. Natural and synthetic trehalose diesters as immunomodulators. Med. Res. Rev. 1986; 6: 243.
- 56Freund J. The mode of action immunological adjuvants. Adv. Tuberc. Res. 1956; 7: 50–5.
- 57Hilleman MR, Woodhour AF, Friedman A, Phelps AH. Studies for safety of Adjuvant 65. Ann. Allergy 1972; 30: 477–80.
- 58Smith JWG, Fletcher WB, Peters M, Westwood M, Perkins FT. Response to influenza vaccine in adjuvant 65–4. J. Hyg. (Lond) 1975; 74: 251–5.
- 59Weibel RE, McLean A, Woodhour AF, Friedman A, Hilleman MR. Ten-year follow-up study for safety of Adjuvant 65 influenza vaccine in man. Proc. Soc. Exp. Biol. Medical 1973; 143: 1053–6.
- 60Woodard LF, Jasman RL. Stable oil-in-water emulsions: preparation and use as vaccine vehicles for lipophilic adjuvants. Vaccine 1985; 3: 57–61.
- 61Kimura J, Nariuchi H, Watanabe T, Matuhasi T, Okayasu I, Hatakeyama S. Studies on the adjuvant effect of water-in-oil-in-water emulsion in sesame oil. I. Enhanced and persistent antibody formation by antigen incorporated into the water-in-oil-in-water emulsion. Jpn J. Exp. Med. 1978; 48: 149–52.
- 62Freestone DS, Hamilton-Smith S, Schild GC, Buckland R, Chinn S, Tyrrel DAJ. Antibody responses and resistance to challenge in volunteers vaccinated with live attenuated, detergent split and oil adjuvant A2-Hong Kong-68 (H 3 N 2) influenza vaccines. A report to the Medical Research Council Committee on Influenza and other Respiratory Virus Vaccines. J. Hyg. (Lond) 1972; 70: 351–5.
- 63Taylor PJ, Miller CL, Pollock TM, Perkins FT, Westwood MA. Antibody response and reactions to aqueous influenza vaccine, simple emulsion vaccine and multiple emulsion vaccine. J. Hyg. (Lond) 1969; 67: 485–90.
- 64Jones GL. Peptide vaccine derived from a malarial surface antigen: effect of dose and adjuvant on immunogenicity. Immunol. Lett. 1990; 24: 253–60.
- 65Shek PN, Yung BYK, Stanacev NZ. Comparison between multilamellar and unilamellar liposomes in enhancing antibody formation. Immunology 1983; 49: 37–40.
- 66Allison AC, Gregoriadis G. Liposomes as immunological adjuvants. Nature 1974; 252: 252–8.
- 67Heath TD, Edwards DC, Ryman BE. The adjuvant properties of liposomes. Biochem. Soc. Trans. 1976; 4: 49–52.
- 68Tyrrel DA, Heath TD, Colley CM, Ryman BE. New aspects of liposomes. Biochim. Biophys. Acta 1976; 457: 259–63.
- 69van Rooijen N, van Nieuwmegen R. Use of liposomes as biodegradable and harmless adjuvants. Meth. Enzymol. 1983; 93: 83–5.
- 70Kramp WJ, Six HR, Kasel JA. Post-immunization clearance of liposome-entrapped adenovirus type 5 hexon. Proc. Soc. Exp. Biol. Medical 1982; 169: 55–9.
- 71Eldrige JH, Staas JK, Meulbroek JA, Tice TR, Gilley RM. Biodegradable microspheres as a vaccine delivery system. Mol. Immunol. 1991; 28: 287–90.
- 72Eldrige JH, Staas JK, Meulbroek JA, Tice TR, Gilley RM. Biodegradable and biocompatible poly (DL-Lactide-Co-Glycolide) microspheres as an adjuvant for Staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect. Immun. 1991; 59: 2978–83.
- 73Xiang Z, Ertl HC. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 1995; 2: 129–35.
- 74Heufler C, Koch F, Schuler G. Granulocyte / macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J. Exp. Med. 1988; 167: 700–5.
- 75Davis SE, Lewis BA. Physiological effects of mannans, galactomannans, and glucomannans. Phys. Effects Food Carb. 1976; 6: 296–311.
- 76Cooper PD. Vaccine Adjuvants Based on Gamma Inulin. In: MF Powell, MJ Newman (eds). Vaccine Design: the Subunit and Adjuvant Approach. New York: Plenum Press, 1995; 559–80.
10.1007/978-1-4615-1823-5_24 Google Scholar
- 77Cooper PD, Steele EJ. Algammulin: a new vaccine adjuvant comprising gamma inulin particles containing alum, preparation and in vitro properties. Vaccine 1991; 9: 351–7.
- 78Cooper PD, McComb C, Steele EJ. The adjuvanticity of Algammulin, a new vaccine adjuvant. Vaccine 1991; 9: 408–15.
- 79Silva D, Cooper PD, Petrovsky N. The search for the ideal adjuvant; inulin derived adjuvants promote both Th1 and Th2 immune responses with minimal toxicity. Immunol. Cell Biol. 2004 (forthcoming).
- 80Tizard IR, Carpenter RH, McAnalley BH, Kemp MC. The biological activities of mannans and related complex carbohydrates. Mol. Biother. 1989; 1: 290–6.
- 81Susuki M, Takatsuki F, Maeda YY, Hamuro J, Chihara G. Lentinan-rationale for development and therapeutic potential. Clin. Immunother. 1994; 2: 121–5.
10.1007/BF03259262 Google Scholar
- 82Sheets MA, Unger BA, Giggleman GF Jr, Tizard IR. Studies of the effect of acemannan on retrovirus infections: clinical stabilization of feline leukemia virus-infected cats. Mol. Biother. 1991; 3: 41–5.
- 83Womble D, Helderman JH. Enhancement of allo-responsiveness of human lymphocytes by acemannan (Carrisyn). Int. J. Immunopharmacol. 1988; 10: 967–74.
- 84McAnalley BH, Carpenter RH, McDaniel HR, inventors. Carrington Laboratories Inc, assignee. Use of acemannan. 1988 August 5, US patent 229164.
- 85Aguilar JC, Muzio VL, Leal MJ, et al. Center of Genetic Engineering and Biotechnology, 1998 September 11, asignee. Immunopotentiating formulations for vaccinal use. WO98/39032.
- 86Morein B, Lövgren K, Höglund S. Immunostimulating complex (ISCOM). In: G Gregoriadis, AC Allison, G Poste (eds). Immunological Adyuvants and Vaccines. New York: Plenum Publishing Corporation, 1989; 153–61.
10.1007/978-1-4757-0283-5_16 Google Scholar
- 87Claassen I, Osterhaus A. The ISCOM structure as an immune-enhancing moiety: experience with viral systems. Res. Immunol. 1992; 143: 531–40.
- 88Larsson M, Lövgren K, Morein B. Immunopotentiation of synthetic oligopeptides by chemical conjugation to ISCOMs. J. Immunol. Meth. 1993; 162: 257–62.
- 89Anderson DJ. The importance of mucosal immunology to problems in human reproduction. J. Rep. Immunol. 1996; 31: 3–19.
- 90Alpar HO, Bowen JC, Brown MRW. Effectiveness of liposomes as adjuvants of orally and nasally administered tetanus toxoid. Int. J. Pharm. 1992; 88: 335–44.
- 91Bye WA, Allan CH, Trier JS. Structure, distribution, and origin of M cells in Peyer's patches of mouse ileum. Gastroenterology 1984; 86: 789–801.
- 92Shalaby WS. Development of oral vaccine to stimulate mucosal and systemic immunity: barriers and novel strategies. Clin. Immunol. Immunopathol. 1995; 74: 127–34.
- 93 PL Ogra, J Mestecky, ME Lamm, W Strober, JR McGhee, J Bienenstock (eds). Handbook of Mucosal Immunology. San Diego: Academic Press, 1996.
- 94Walker RI. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 1994; 12: 387–400.
- 95McGhee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M, Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 1992; 10: 75–88.
- 96Elson CO. Cholera toxin as a mucosal adjuvant: the effect of H-2 genes. Fed. Proc. 1987; 46: 1778–82.
- 97Snider DP. The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins. Crit. Rev. Immunol. 1995; 15: 317–48.
- 98Li Wan Po A, Rogers E, Shepphard M, Scott EM. Delivery systems for non-parenteral vaccines. Advanced Drug Delivery Rev. 1995; 18: 101–9.
- 99Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Tice TR. Controlled vaccine release in the gut-associated lymphoid tissues. Orally administered biodegradable microspheres target the Peyer's patches. J. Controlled Release 1990; 11: 205–14.
- 100Jani P, Halbert GW, Langridge J, Florence AT. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J. Pharm. Pharmacol. 1990; 42: 821–6.
- 101Alpar HO, Field WN, Hyde R, Lewis DA. The transport of microspheres from gastrointestinal tract to imflammatory air pouches in the rat. J. Pharm. Pharmacol. 1989; 41: 194–6.
- 102Neutra MR, Kraehenbuhl JP, Frey A, Epithelial M. Cells: Gateways for Mucosal Infection Immunization. Cell 1996; 86: 345–8.
- 103Frey A, Giannasca KT, Weltzing R et al. Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implication for microbial attachment and oral vaccine targeting. J. Exp. Med. 1996; 184: 1045–59.
- 104Mekalanos JJ. Bacterial mucosal vaccines. Adv. Exp. Med. Biol. 1992; 327: 43–50.
- 105Zhang Z, Michael J. Orally inducible immune unresponsiveness is abrogated by IFN-g treatment. J. Immunol. 1990; 144: 4163–5.
- 106Marinaro M, Boyaka PN, Finkelman FD et al. Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses. J. Exp. Med. 1997; 185: 415–27.
- 107Kim JJ, Bagarazzi ML, Trivedi N et al. Nature Biotechnology 1997; 15: 641–6.
- 108Tsuji T, Hamajima K, Fukushima J et al. Enhancement of Cell-Mediated Immunity Against HIV-1 Induced by Coinoculation of Plasmid-Encoded HIV-1 Antigen with Plasmid Expressing IL-12. J. Immunol. 1997; 158: 4008–13.
- 109Alpar HO. Particulated carriers for mucosal delivery of vaccines. Biochem. Soc. Trans. 1997; 25: 337S.
- 110Sasaki S, Fukushima J, Hamajima K et al. Adjuvant effect of Ubenimex on a DNA vaccine for HIV-1. Clin. Exp. Immunol. 1998; 111: 30–5.
- 111Sasaki S, Hamajima K, Fukushima J et al. Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type 1 with a DNA-monophosphoryl lipid A adjuvant vaccine. Infect. Immun. 1998; 66: 823–6.
- 112Pisetsky DS, Immunostimulatory DNA. A clean and present danger. Nature Med. 1997; 3: 829–31.
- 113Herlyn D, Birebent B. Advances in cancer vaccine development. Ann. Med. 1999; 31: 66–78.
- 114Kochman S, Bernard J. Antitumour immune response and cancer vaccination: the critical role of dendritic cells. Curr. Med. Res. Opin. 1999; 15: 321–6.
- 115Estevez F, Carr A, Solorzano L et al. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine 1999; 18: 190–7.
- 116Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin. Cancer Res. 1999; 5: 1289–97.